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Purpose: Since the role of short- and long-term intraocular pressure (IOP) fluctuation as a 
predictor of glaucoma progression is still controversial, the purpose of this study was to inves-
tigate the role of IOP fluctuation in a non-selected patient cohort.
Materials and methods: Two-hundred and forty eyes of 120 glaucoma patients (51% female) 
with a mean age of 64.5 years were included. Inclusion criteria were at least a visual field (VF) 
and a 48-hour diurnal phasing of IOP including nocturnal measurement. Glaucoma progression 
was defined as – if available – confirmed progression of reproducible VF defects in at least three 
VF examinations or increase of cup area on optic nerve imaging (Heidelberg Retina Tomograph 
[HRT]) with at least two images after baseline. If results were stable or less than previously 
mentioned VF or HRT examinations were available, it was classified as “no progression”.
Results: Glaucoma progression was seen in seven of 240 eyes in the VF analysis and ten 
of 240 eyes on HRT. Of all 240 eyes, 92 and 41 eyes fulfilled the criteria to be included for 
progression evaluation on VF and HRT analysis, respectively. Mean time to progression ± 
standard error was 3.6±0.2 years on VF and 4.5±0.3 years on HRT. Univariate and multivariate 
Cox regression analyses revealed short-term IOP fluctuation (P,0.0001) and maximum IOP 
(P,0.001) as risk factors for glaucoma progression on VF. There was no significant influence 
of demographic characteristics, ocular or general health on glaucoma progression.
Conclusion: Short-term IOP fluctuation was associated with the progression of glaucoma in 
this non-selected cohort of glaucoma patients receiving phasing of IOP.
Keywords: glaucoma progression, short-term IOP fluctuation, long-term IOP fluctuation, 
glaucoma imaging, visual field
Introduction
The detection of glaucoma progression is still of crucial importance for the treatment 
of glaucoma patients but remains challenging despite new and advanced diagnostic 
technologies. Assessing the function and structure in glaucoma is essential for detect-
ing glaucomatous deterioration.1 For function, visual field (VF) testing with standard 
automated perimetry (SAP) is used for diagnosing, follow-up, and management of 
glaucoma. True VF progression is confirmed by computer-assisted analyses such 
as event- (progression or no progression)2 and trend-analysis (rate of progression).1 
For structure, imaging devices such as the Heidelberg Retina Tomograph (HRT) can 
quantify glaucomatous progression of the optic nerve head by comparing baseline 
with follow-up images of the same patient.1,3,4
One of the most important risk factors for development and progression of glau-
coma is a high intraocular pressure (IOP) and lowering the IOP is known to slow 
vision loss.5–11 However, it is difficult to define the impact of IOP fluctuation on 
glaucoma progression due to the variable definition of IOP fluctuation, timing of 
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IOP measurements, and lack of standardization of the IOP 
measurement itself.12–14 
A common definition of short-term IOP fluctuation is the 
IOP difference between the highest and lowest IOP over the 
course of 24 hours or less.12 In general, IOP has a tendency 
to fluctuate throughout the day reaching its peak in the early 
morning or in supine position as well as over periods of 
time in healthy subjects or glaucoma patients.14–19 Numerous 
studies have demonstrated a correlation between short-term 
IOP fluctuation and glaucoma progression,19–23 whereas other 
studies reported no significant association.16,24–27 
In contrast to short-term, long-term IOP fluctuation is less 
well-defined but it is often described as IOP difference or 
deviation over a period (weeks, months) measured on several 
occasions throughout the day and on different days.6,7,13,28–33 
Similar to studies on short-term IOP fluctuation and glaucoma 
progression, long-term IOP variation is also controversial in 
the literature.6,7,28–35 A large study on the significant influence 
of long-term IOP fluctuation was the Advanced Glaucoma 
Intervention Study (AGIS), which included refractory open-
angle glaucoma (OAG) patients who were not controlled 
by medication and found for each mmHg increase in IOP 
fluctuation the risk of VF progression increased by 30% in 
the course of the disease.32 However, the inclusion criteria 
to calculate VF progression were criticized and a follow-up 
study was published addressing this limitation by limiting 
the inclusion of IOP levels to the first VF deterioration.13 
This significant effect of long-term IOP fluctuation on 
glaucoma progression could however not be confirmed by 
other studies.6,9,28,31,34 Nevertheless, IOP remains a proven, 
modifiable risk factor which could potentially decrease the 
risk of progression. It is therefore important to focus on IOP 
and IOP fluctuation and its role on glaucoma progression in 
future studies. Several reviews have been published so far 
and addressed the controversy of the role of IOP fluctuation 
in the development and progression of glaucoma.36–39
The accurate measurement of IOP fluctuation requires 
phasing of IOP measured several times during the day, on 
different days, and over a long period. Such IOP profiles 
were taken routinely and regularly in glaucoma patients 
since the early 1990s at the Department of Ophthalmology, 
University Medical Center in Mainz. In order to investigate 
the role of IOP fluctuation on glaucoma progression, a certain 
number of IOP profiles were required. The aim of this ret-
rospective study was therefore to investigate short-term and 
long-term fluctuation of IOP, as well as general and ocular 
characteristics as risk factors for glaucoma progression in 
a non-selected patient cohort. By including all available 
patient data without strict inclusion and exclusion criteria in 
evaluating glaucoma progression, we wish to predict the risk 
of progression based on baseline characteristics in a clinical 
setting rather than the number of VF or imaging examina-
tions in a well-controlled study setting. This approach may 
better reflect everyday practice with heterogeneous patient 
information for early detection of glaucoma progression 
enabling earlier treatment for patients with progression, 
but also saving many suspected glaucoma patients years of 
needless follow-up.
Materials and methods
The study was approved by the local ethics committee of the 
Landesärztekammer Rheinland-Pfalz in Mainz, Germany. 
The research followed the tenets of the Declaration of 
Helsinki. No patient consent was necessary for this retrospec-
tive study. All data were collected and stored in accordance 
with the legislation on data confidentiality.
Two-hundred and forty eyes of 120 glaucoma patients 
from a random list of glaucoma patients treated at the 
Department of Ophthalmology, University Medical Center 
Mainz, Germany between 2004 and 2009 were enrolled in 
this longitudinal retrospective cohort study. Inclusion criteria 
were glaucoma patients with at least 48 hours phasing of IOP 
during the day and an IOP measurement at night in supine 
position and a VF on SAP using Humphrey Visual Field 
Analyzer (HFAII; Carl Zeiss Meditec AG, Jena, Germany) 
24-2 and 30-2 strategy or Octopus 900 perimeter (Haag-Streit 
Holding AG, Köniz, Switzerland).
iOP
Goldmann applanation tonometry was routinely used 
during diurnal and the handheld Perkins tonometer (both 
Haag-Streit Holding AG) for nighttime IOP measurements 
in supine position. Approximately four IOP measurements 
during the day (at 8 am, 2 pm, 6 pm, and 9 pm) and one at 
night (at 12 am) were available for every patient (total of 
approximately ten measurements over 48 hours). Baseline 
IOP was defined by calculating the mean value of IOP 
measured during the first 48 hours phasing. Mean and SD 
values were calculated, as well as highest IOP defined as 
maximum IOP during phasing. Short-term IOP was defined 
as IOP within 48 hours phasing and long-term IOP over a 
period of months and years.
Definition of progression
Progression was defined as the first detected change on either 
VF or HRT. A confirmed progression required repeatable 
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VF defects on perimetry or thinning of the rim on HRT in 
subsequent examinations. Reproducible VF defects in at 
least three VF examinations or increase of cup area on HRT 
analysis with at least two optic disc images after the baseline 
examination was seen as glaucoma progression. Evaluation 
of progression as reproducible change of VF defects and 
significant thinning of the optic disc rim was performed by 
an experienced glaucoma surgeon and consultant (EMH).
VF
SAP with HFAII or Octopus perimeter was evaluated for 
progression of VF defects. Progression of VF was defined 
as a reduction in sensitivity in three or more contiguous 
points with P,0.01 or one point with P,0.05 on the pattern 
deviation plot. Progression was distinguished between 
“possible progression” (first detected progression), “likely 
progression” (progression in two VFs), and “confirmed 
progression” (progression in all three VFs).
Optic disc imaging
Topographic change analysis (TCA) of the HRT (HRTII 
and III, Heidelberg Engineering GmbH, Heidelberg, 
Germany) was used to evaluate structural progression of 
rim thinning. Significant cluster building in the super pixel 
analysis was used for progression definition. Progression was 
defined as “possible progression” (first detected progression) 
to “confirmed progression” (significant cluster existence in 
the TCA analysis). More short- and long-term follow-up 
data of optic disc morphology from HRT were available 
than imaging on optical coherence tomography and were 
therefore used for this study.
statistical analyses
Statistical analyses were performed with SPSS for 
Windows 22 (IBM Corporation, Armonk, NY, USA). Base-
line patient characteristics were given as mean and SDs for 
continuous variables, absolute and relative frequencies for 
categorical variables, and were tested for association with 
glaucoma progression by using a logistic model with the 
generalized estimation equation method for each explanatory 
variable. Univariate Cox regression analyses were used to 
evaluate the association between short- and long-term IOP 
fluctuation and glaucoma progression. Survival analyses were 
performed to identify progression-free survival time using VF 
and HRT analysis for the detection of glaucoma progression 
with IOP as the time-dependent covariable. Cox models with 
time-dependent covariates were used to evaluate predictor 
variables at each observed progression time. In Cox model 
analyses, we adjusted for dependency between eyes of a 
patient using the method of Lee et al.40 Multivariable models 
were adjusted for age, gender, short- and long-term IOP 
measurements. For all analyses listed, a P-value of ,0.05 
was considered statistically significant.
Results
Data of 240 eyes of 120 patients (51% female) with a 
mean age of 64.5±13.2 years (range 20–89 range) were 
screened. Mean baseline IOP was 15.8±2.8 mmHg for 
all patients with the majority having primary OAG; 64%. 
Patients’ characteristics are illustrated in Table 1. Of the 
240 eyes, 92 and 41 eyes fulfilled the criteria to be included 
for progression evaluation with at least four VF or three 
HRT examinations, respectively. Glaucoma progression 
was seen in seven of 240 eyes in the VF analysis and ten 
of 240 eyes on HRT.
regression analysis of iOP parameters 
and glaucoma progression
Univariate Cox regression analysis showed a significant 
association between short-term SD of IOP (HR 1.15, 95% CI 
1.07–1.23, P,0.0001), short-term maximum IOP (HR 1.05, 
95% CI 1.02–1.07, P,0.0001, per mmHg), long-term 
maximum IOP (HR 1.04, 95% CI 1.02–1.07, P,0.0001), 
Table 1 Patients’ characteristics
Patients/eyes, n 120/240
Patients/eyes, n included in the 
progression analysis
 
On visual field 47/92
On hrT 21/41
age, years  
Mean ± sD (range) 64.5±13.2 (20–89)
gender (%)  
Male 59 (49.2)
Female 61 (50.8)
Type of glaucoma (%)  
POag 77 (64.2)
PeXg 21 (17.5)
nTg 6 (5.0)
Pg 5 (4.2)
Othersa 11 (9.2)
Baseline iOP, mmhg  
Mean ± sD 15.8±2.8
Follow-up, years  
Mean ± sD (range) 3.5±4.0 (0–21)
Notes: Data are absolute values (%), mean ± sD. aOthers: secondary glaucoma, 
chronic angle-closure glaucoma, and ocular hypertension.
Abbreviations: hrT, heidelberg retina Tomograph; iOP, intraocular pressure; 
nTg, normal tension glaucoma; PeXg, pseudoexfoliation glaucoma; Pg, pigmentary 
glaucoma; POag, primary open-angle glaucoma.
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and glaucoma progression on VF (Table 2), but we failed to 
detect significant association between short- and long-term 
mean IOP and VF progression.
In the time-dependent multivariate Cox regression 
analysis short-term SD of IOP (HR 1.37, 95% CI 1.18–1.59, 
P,0.0001) and short-term maximum IOP (HR 1.06, 
95% CI 1.03–1.10, P=0.0005) were also significant predic-
tive factors for glaucoma progression on VF (Table 2). There 
was no significant association found between long-term 
IOP parameters and glaucoma progression.
risk factors of glaucoma progression
General characteristics (age, gender, and family history 
of glaucoma), myopia (spherical error of more than -3.00 
diopters), central corneal thickness (less than 520 µm), and 
general health (migraine, arterial hypertension and hypoten-
sion, peripheral vascular diseases, autoimmune disease, 
diabetes, and coronary heart disease) did not significantly 
influence glaucoma progression on VF or HRT.
Progression-free time
Overall mean progression-free time was 2.4±0.9 years 
on VF and 3.1±0.6 years on HRT including all patients. 
Mean progression-free time was 3.6±0.2 years on VF and 
4.5±0.3 years on HRT when considering patients who met 
the criteria for evaluating glaucoma progression (92 eyes on 
VF and 41 eyes on HRT).
Survival analysis revealed a cumulative progression-free 
survival ratio of 75% after 6.9 years on VF in patients with 
data available for progression analysis (Figure 1). Mean 
progression-free time was 6.6 years on HRT with a survival 
ratio of 50% (Figure 2).
Discussion
Short-term and long-term IOP fluctuations are worth con-
sidering as a risk factor for glaucoma progression. However, 
the definition and measurement of IOP fluctuation are incon-
sistent among studies. Moreover, inclusion and exclusion 
criteria widely differ between studies. We have included 
all available data to evaluate short-term and long-term 
fluctuation of IOP as a risk factor for glaucoma progression. 
This may reflect more heterogeneous patients’ information 
of everyday practice rather than a study with many inclu-
sion and exclusion criteria. We found a progression rate 
of 7/240 eyes on VF and 10/240 eyes on HRT. Analysis 
of risk factors did not reveal any significant influence of 
Table 2 iOP and glaucoma progression on VF
 HRa 95% CI P-value
Univariate analysis
Mean    
short-term iOP 1.09 0.96–1.24 0.19
long-term iOP 1.04 0.93–1.16 0.46
sD    
short-term iOP 1.15 1.07–1.23 ,0.0001
long-term iOP 0.98 0.70–1.35 0.88
Max    
short-term iOP 1.05 1.02–1.07 ,0.0001
long-term iOP 1.04 1.02–1.07 0.001
Multivariate analysisb
Mean    
short-term iOP 1.35 0.65–2.82 0.42
long-term iOP 0.75 0.27–2.09 0.59
sD    
short-term iOP 1.37 1.18–1.59 ,0.0001
long-term iOP 0.76 0.49–1.18 0.21
Max    
short-term iOP 1.06 1.03–1.10 0.0005
long-term iOP 1.27 0.98–1.64 0.07
Notes: aUnivariate and multivariate Cox regression analysis of glaucoma pro gression 
on VF. eighty-six eyes of 44 patients with primary open-angle, pseudoexfoliation and 
normal tension glaucoma were included; patients with pigmentary glaucoma and 
other glaucoma did not progress. bThree multivariable models were fitted, one for 
each of mean, sD, and max. each model included gender, age, and one short-term 
and long-term iOP parameter. short-term iOP parameters were derived from the 
latest IOP profile. Long-term parameters were derived from means of short-term 
IOP profiles up to the latest visit. Bold text indicates statistical significant results.
Abbreviations: iOP, intraocular pressure; max, maximum; sD, standard deviation; 
VF, visual field.
???????
??????
??????
?? ?? ??
????????????????????????????????????????????????????????????????????????? ?? ?????????????
????????????????
????????
?? ??? ???
Figure 1 glaucoma progression on VF.
Notes: Kaplan–Meier plot shows progression-free time on VF. survival analysis 
revealed a cumulative progression-free survival proportion of 75% after 6.9 years 
on VF in patients with data available for progression analysis. Patients were counted 
as having “confirmed progression” or “no progression” until the time of the last 
follow-up or if the definitions of progressions were not fulfilled and were marked as 
censored. Others include normal tension glaucoma, pigmentary glaucoma, secondary 
glaucoma, chronic angle-closure glaucoma, and ocular hypertension.
Abbreviations: PeXg, pseudoexfoliation glaucoma; POag, primary open-angle 
glaucoma; VF, visual field.
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demographic characteristics, ocular or general health on 
glaucoma progression. Mean progression-free time was 
2.4±0.9 years on VF and 3.1±0.6 years on HRT including all 
patients. We have shown a significant association between 
short-term IOP, however not long-term IOP fluctuation, 
and glaucoma progression. Interestingly, only the deviation 
and maximum short-term but not the mean IOP fluctuation 
were significantly associated with glaucoma progression. 
IOP spikes appear to be more harmful and may be missed 
when studying mean IOP fluctuation rather than the SD or 
highest IOP values. However, the question still remains 
why diurnal short-term IOP fluctuation over the course of a 
day or two contributes more to glaucoma progression than 
long-term fluctuation. The findings in previous studies are 
also somewhat controversial. Studies on short-term IOP 
fluctuation have demonstrated an association with glaucoma 
progression19–23 whereas others did not.16,24–27 Of those with 
significant IOP variation, Grippo et al20 showed that 30% 
of patients with untreated ocular hypertension (OHT) have 
a similar 24-hour IOP pattern to those with glaucoma, such 
as diurnal and nocturnal IOP variation and IOP changes in 
sitting and supine positions. Especially diurnal IOP fluctua-
tion was greater in OHT and glaucoma patients compared to 
healthy participants.20 In a population-based study sample, 
Thomas et al23 found a 5-year incidence of glaucoma in 
patients with OHT of 17.4%. Short-term mean and peak 
IOP were higher and a diurnal IOP variation of more than 
8 mmHg often occurred in patients who progressed.23 A 
large study by Jonas et al21 analyzing over 3,500 IOP profiles 
from 720 patients (majority with different types of OAG 
including normal tension glaucoma [NTG] compared to 
healthy participants) found a significant IOP fluctuation in 
patients with secondary OAG compared to healthy eyes or 
NTG patients.21 The same study group published a report 
of 458 patients (174 eyes with OHT, 681 eyes with POAG) 
3 years earlier and found an association of mean, peak, and 
trough IOP with glaucoma progression but no significant 
correlation of IOP amplitude and glaucoma progression.24 
A sub-analysis even showed a negative association of 
IOP variation and progression in NTG. Likewise, Sung et 
al26 reported on 101 NTG patients over 6 years, of whom 
almost one-third progressed and found that ocular perfu-
sion pressure but not IOP, was significantly associated with 
progression.
Similar controversial results can be found for long-term 
IOP fluctuation and glaucoma progression.6,7,28–35 The AGIS 
study,32 a large prospective, multicenter and randomized 
clinical trial including 509 eyes of 401 patients, investigated 
risk factors associated with VF progression and found older 
age (OR 1.30, 95% CI 1.11–1.50), larger long-term IOP 
fluctuation (OR 1.31, 95% CI 1.12–1.54), increasing number 
of glaucoma interventions (OR 1.74, 95% CI 1.14–2.64), 
and longer follow-up (OR 1.19, 95% CI 1.03–1.38) to be 
significantly associated with VF progression. The odds of 
VF progression increased by 30% for each 5-year increment 
in age and 1 mmHg increase in IOP fluctuation.32 However, 
a limitation of this first analysis was that prognostic factors 
used to predict progression were measured before and after 
VF progression. This would have meant an increased IOP 
fluctuation as patients progressed and treatment was esca-
lated. Therefore, a follow-up study was published using the 
same data from the AGIS with the inclusion of only IOP data 
of patients (with only one surgical intervention, if any) until 
the first evidence of VF progression to evaluate the risk of 
IOP fluctuation in glaucoma progression.13 Further to this, 
Hong et al studied glaucoma patients after combined cataract 
surgery and trabeculectomy and showed over 3 years that 
one-third of patients with IOP fluctuation of more than 2 
mmHg progressed compared to only 10% with SD of IOP 
of less than 2 mmHg.29 This is in contrast to a randomized 
cohort from the Early Manifest Glaucoma Trial6 with 129 
treated glaucoma patients and 126 controls which found that 
???????
??????
??????
?? ?? ??
????????????????????????????????????????????????????????????????????????? ?? ?????????????
????????????????
????????
?? ???
Figure 2 glaucoma progression on optic disc imaging.
Notes: Kaplan–Meier plot shows progression-free time on heidelberg retina 
Tomograph (hrT). Mean progression-free time was 6.6 years on hrT with a 
survival ratio of 50%. Patients were counted as having “confirmed progression” 
or “no progression” until the time of the last follow-up or if the definitions of 
progressions were not fulfilled and were marked as censored. Others include 
normal tension glaucoma, pigmentary glaucoma, secondary glaucoma, chronic angle-
closure glaucoma, and ocular hypertension.
Abbreviations: hrT, heidelberg retina Tomograph; PeXg, pseudoexfoliation 
glaucoma; POag, primary open-angle glaucoma.
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
4.
93
.1
7.
18
0 
on
 2
0-
De
c-
20
18
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Ophthalmology 2019:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
14
Matlach et al
Table 3 selection of studies on iOP indices and glaucoma progression
Author(s), year, journal Patient groups Results
Studies with significant short-term IOP fluctuation and glaucoma progression
David et al, 1992, BJO19 690 diurnal curves (OhT, Oag, 
CaCg, others, healthy eyes)
Significant difference in IOP variation between healthy, OAG, 
and CaCg.
Thomas et al, 2003, Indian J Ophthalmol23 23 OhT patients 17% progressed. Bilateral OhT, higher peak iOP, and large diurnal 
iOP variation were risk factors for progression.
Tajunisah et al, 2007, Graefes Arch Clin 
Exp Ophthalmol22
202 eyes with Oag, nTg, 
OhT or suspected glaucoma
100 healthy eyes
IOP variance was significantly higher in glaucoma or suspected 
glaucoma patients than in healthy patients.
Jonas et al, 2010, J Ophthalmic Vis Res21 1,072 Oag eyes (POag, 
sOag, nTg, others)
336 healthy eyes
IOP fluctuation was significantly higher in SOAG patients than in 
nTg or healthy patients.
grippo et al, 2013, IOVS20 24 healthy
15 OhT patients
24 glaucoma patients
Significant diurnal sitting and supine IOP variation between all groups. 
no nocturnal difference. 33% of OhT converted to glaucoma.
Studies with no significant short-term IOP fluctuation and glaucoma progression
Jonas et al, 2007, Eye (Lond)24 174 eyes with OhT
681 eyes with POag
No significant association between IOP amplitude and glaucoma 
progression (19% progression rate).
sung et al, 2009, IOVS26 101 nTg patients 29% progressed. Ocular perfusion pressure but not iOP itself was 
significantly associated with progression.
sehi et al, 2011, J Glaucoma25 14 untreated POag patients
14 healthy
No significant association between diurnal IOP change and optic 
nerve appearance on hrT.
Wang et al, 2011, IOVS27 47 untreated POag patients No significant association between 24 hours IOP fluctuation and 
VF progression. No significant difference in IOP between the 
glaucomatous and non-glaucomatous eye.
lee et al, 2012, IOVS16 177 nTg patients no correlations between 24-hour iOP parameters and VF results.
Studies with significant long-term IOP fluctuation and glaucoma progression
nouri-Mahdavi et al, 2004, 
Ophthalmology32
advanced glaucoma intervention study
401 refractory Oag patients For each mmHg increase in IOP fluctuation, the risk of VF 
progression increased by 30%.
hong et al, 2007, Arch Ophthalmol29 408 eyes (POag, PaCg) after 
combined cataract surgery + 
trabeculectomy
30% progressed with iOP sD .2 mmhg compared to 10% with 
iOP sD ,2 mmhg (over at least 3 years).
lee et al, 2007, Am J Ophthalmol30 151 patients with POag, nTg, 
OhT or suspected glaucoma 
SD of IOP was significantly associated with progression. Each mmHg 
increase in iOP sD increased the likelihood of progression by a 
factor of 5.5.
Fukuchi et al, 2013, J Glaucoma35 121 high-tension Oag patients
166 nTg patients
nTg fast-progressors had a greater iOP sD and larger iOP 
fluctuation than non-progressors. High-tension OAG had a higher 
mean IOP but not IOP fluctuation.
rao et al, 2013, J Glaucoma33 213 treated POag or PaCg 
patients
Long-term IOP fluctuation was associated with increased VF 
progression (worsened by 0.35%/year for every mmhg increase in 
fluctuation).
(Continued)
long-term IOP fluctuation was not related to progression 
(HR 1.00, 95% CI 0.81–1.24, P=0.999). In addition, Bengts-
son and Heijl also examined 90 high-risk OHT patients in the 
Malmö Ocular Hypertension Study34 every 3 months with 
office-hours diurnal IOP phasing and perimetry. Patients 
were prospectively followed-up for 10 years or until glau-
comatous VF loss was seen. Forty-one percent developed 
glaucoma with VF defects. IOP level (95% CI 1.09–1.38), but 
not IOP fluctuation (95% CI 0.80–1.60) was as a significant 
risk factor for developing glaucoma. They concluded that IOP 
fluctuation was not an independent risk factor for glaucoma 
progression on VF in patients with high-risk OHT.34 A selec-
tion of relevant literature on IOP fluctuation and glaucoma 
progression is summarized in Table 3.
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IOP fluctuation as risk for glaucoma progression
Several limitations of our study have to be discussed. First, 
this was a retrospective collection of data with a risk of bias 
and confounding. Second, as our study reflects daily prac-
tice, patients without any progression may not have received 
intensive follow-up as fast-progressing patients. By includ-
ing all patients’ data for evaluating glaucoma progression, 
we have tried to address the problem of pre-selecting data. 
The classification of progression and non-progression was 
subjective without masking to structural or functional tests 
or IOP readings. Also, grading of glaucoma progression or 
no progression was performed by a single experienced glau-
coma specialist without determining the individual test–retest 
reproducibility. Third, we have included a variety of patients 
with different types of glaucoma, eg, POAG, NTG, and 
secondary glaucoma. This may have affected the progression 
rate because different glaucoma types progress faster than 
others. Fourth, results of multivariate Cox regression analysis 
should be interpreted with caution since only a small number 
of patients with progression on VF or HRT were included. 
The last and important weakness of our study was the fact 
that glaucoma treatment may change during follow-up if 
progression is suspected. This would have caused biases 
in the conclusion of our study, which should therefore be 
interpreted with caution.
Conclusion
Our results show that short-term, but not long-term IOP 
fluctuation influences the progression of glaucoma. Analysis 
of risk factors did not reveal any significant influence of 
demographic characteristics, ocular or general health on 
glaucoma progression. Time to progression was fairly similar 
for VF and HRT analysis. Prospective clinical trials are 
needed to answer the question of whether or not short-term 
or long-term IOP fluctuation is a risk factor of glaucoma 
progression.
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